Chen WL, Wang JH, Zhao AH et al.
Shanghai Jiao Tong University, Shanghai, China.
Rob Sellar’s review: Abnormalities of glucose metabolism, including of glycolysis and the tricarboxylic acid (TCA) cycle, have been found in cancer cells and linked to both treatment resistance and clinical outcome. In acute myeloid leukemia (AML), an intermediate metabolite of the TCA cycle, 2-hydroxyglutarate (2-HG), is produced by mutant isocitrate dehydrogenases 1 and 2, and implicated in leukemogenesis (Proc Natl Acad Sci U S A 2013;110:17017–22).
The authors of the current study sought to explore alterations of glucose metabolism in AML and how they relate to clinical outcomes. A metabolomic analysis of serum using mass spectrometry and focusing on glucose metabolism was performed on samples that were collected from 229 patients at diagnosis of de novo AML and from 260 healthy controls. Among the 100 metabolites of glucose metabolism that were identified, six (lactate, 2-oxoglutarate, pyruvate, 2-HG, glycerol-3-phosphate, and citrate) were differentially expressed in sera from patients with AML compared with healthy controls, in the initial cohort as well as in a validation set.